Abstract 2773: 3D Predict™, an analytically and clinically validated platform for evidence-based functional precision medicine
Authors: Rayner Melissa , Miles Katherine , Burgess Kimberly , Brooks Taylor , Elrod Ashley K. , Williams Natalie A. , Stuart Jeremy , Holmes Lillia , DesRochers Teresa M. 
Published: June 2022

Abstract
Treatment paradigms for cancer patients have evolved as technology has advanced. Initial treatment guidelines were developed from probability-based assessments of the likelihood of groups of patients to respond to a compound. Biomarkers such as HER2 further added to the strength of therapy direction. The advent of next-generation sequencing (NGS) facilitated the use of gene mutations to direct patients to targeted chemotherapies. The one thing in common for each of these methods is a lack of functional assessment of each patient’s own tumor cells when in direct contact with the therapy being considered. Advanced live cell preservation methods combined with innovative cell culture techniques have facilitated a new paradigm for guiding therapy decisions. 3D Predict™ uses 3D cell culture to place each patient’s own tumor cells into direct contact with a panel of potential therapies. Individual response dynamics to each therapy are assessed thereby producing a patient-specific therapeutic response prediction. 95% of samples are successfully assayed with both response and non-response predictions being useful in therapy guidance, and data is returned within 7 business days of a patient’s surgical resection providing results within an actionable window. This platform has been analytically validated for use in high-grade gliomas (HGG) and ovarian cancer, it has been clinically validated in both HGG and ovarian cancer, and it is commercially available for use in HGG. 3D Predict™ Glioma, when judged against clinical outcomes, is 85% accurate in the prediction of response to temozolomide for newly diagnosed patients and has been shown to more than double the progression-free survival of relapsed patients in the clinical study 3D-PREDICT (NCT03561207). When the ovarian assay is judged against clinical outcomes, it is 89% accurate in the prediction of response to carboplatin/paclitaxel for newly diagnosed patients. Here we present the continued growth of the 3D Predict™ pipeline, including validation in rare cancers, breast cancer, and non-small cell lung cancer and the adaptation of the platform for the use of single core biopsies. Utilization of the 3D Predict™ platform can help patients with tumor types that have little to no guidance metrics for treatment decisions, improve the accuracy of biomarker-based direction, and increase the precision of NGS-based response predictions.
Citation Format: Melissa Rayner, Katherine Miles, Kimberly Burgess, Taylor Brooks, Ashley K. Elrod, Natalie A. Williams, Jeremy Stuart, Lillia Holmes, Teresa M. DesRochers. 3D Predict™, an analytically and clinically validated platform for evidence-based functional precision medicine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2773.